James B Wetmore1,2, Jonathan D Mahnken3, Milind A Phadnis3, Edward F Ellerbeck4, Theresa I Shireman4,5. 1. Division of Nephrology, Hennepin County Medical Center, Minneapolis, MN, USA. 2. Chronic Disease Research Group, Minneapolis, MN, USA. 3. Departments of Biostatistics. 4. Preventive Medicine and Public Health, Kansas City, KS, USA. 5. The Kidney Institute, University of Kansas School of Medicine, Kansas City, KS, USA.
Abstract
BACKGROUND AND OBJECTIVE: The comparative effectiveness of dihydropyridine (DHP) and non-DHP calcium channel blockers (CCBs) in maintenance dialysis patients has not been well-studied. METHODS: A retrospective cohort of hypertensive patients initiating dialysis was created. New CCB initiators, defined as individual who had no evidence of CCB use in the first 90 days of dialysis but who were initiated by day 180, were followed from their first day of medication exposure until event or censoring; events consisted of all-cause mortality (ACM) and a combined endpoint of cardiovascular morbidity or mortality (CVMM). Cox proportional hazards models were used to determine adjusted hazard ratios (AHRs) comparing the effect of DHPs vs. non-DHPs. RESULTS: There were 2900 and 2704 new initiators of CCBs in the ACM and CVMM models, respectively. Adjusted for other factors, use of DHPs, compared to non-DHPs, was associated with an AHR of 0.77 (99% confidence intervals, 0.64 - 0.93, P = 0.0004) for ACM and 0.86 (0.72 - 1.02, P = 0.024) for CVMM. Results were similar when individuals who initiated therapy at any point after the cohort inception were included, with AHRs of 0.60 (0.53 - 0.69, P < 0.0001) and 0.77 (0.67 - 0.89, P < 0.0001) for ACM and CVMM, respectively. Further, elimination of individuals with chronic atrial fibrillation resulted in AHRs of 0.71 and 0.70 for ACM and CVVM, respectively. CONCLUSION: DHPs, as compared to non-DHPs, were associated with reduced hazard of death or cardiovascular morbidity and mortality; potential mechanisms of action require further study.
BACKGROUND AND OBJECTIVE: The comparative effectiveness of dihydropyridine (DHP) and non-DHPcalcium channel blockers (CCBs) in maintenance dialysis patients has not been well-studied. METHODS: A retrospective cohort of hypertensivepatients initiating dialysis was created. New CCB initiators, defined as individual who had no evidence of CCB use in the first 90 days of dialysis but who were initiated by day 180, were followed from their first day of medication exposure until event or censoring; events consisted of all-cause mortality (ACM) and a combined endpoint of cardiovascular morbidity or mortality (CVMM). Cox proportional hazards models were used to determine adjusted hazard ratios (AHRs) comparing the effect of DHPs vs. non-DHPs. RESULTS: There were 2900 and 2704 new initiators of CCBs in the ACM and CVMM models, respectively. Adjusted for other factors, use of DHPs, compared to non-DHPs, was associated with an AHR of 0.77 (99% confidence intervals, 0.64 - 0.93, P = 0.0004) for ACM and 0.86 (0.72 - 1.02, P = 0.024) for CVMM. Results were similar when individuals who initiated therapy at any point after the cohort inception were included, with AHRs of 0.60 (0.53 - 0.69, P < 0.0001) and 0.77 (0.67 - 0.89, P < 0.0001) for ACM and CVMM, respectively. Further, elimination of individuals with chronic atrial fibrillation resulted in AHRs of 0.71 and 0.70 for ACM and CVVM, respectively. CONCLUSION:DHPs, as compared to non-DHPs, were associated with reduced hazard of death or cardiovascular morbidity and mortality; potential mechanisms of action require further study.
Authors: Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff Journal: J Am Coll Cardiol Date: 2013-06-05 Impact factor: 24.094
Authors: Henry R Black; William J Elliott; Gregory Grandits; Patricia Grambsch; Tracy Lucente; William B White; James D Neaton; Richard H Grimm; Lennart Hansson; Yves Lacourciere; James Muller; Peter Sleight; Michael A Weber; Gordon Williams; Janet Wittes; Alberto Zanchetti; Robert J Anders Journal: JAMA Date: 2003 Apr 23-30 Impact factor: 56.272
Authors: Todd F Griffith; Benjamin S Y Chua; Andrew S Allen; Preston S Klassen; Donal N Reddan; Lynda A Szczech Journal: Am J Kidney Dis Date: 2003-12 Impact factor: 8.860
Authors: Wendy L St Peter; Stephen M Sozio; Tariq Shafi; Patti L Ephraim; Jason Luly; Aidan McDermott; Karen Bandeen-Roche; Klemens B Meyer; Deidra C Crews; Julia J Scialla; Dana C Miskulin; Navdeep Tangri; Bernard G Jaar; Wieneke M Michels; Albert W Wu; L Ebony Boulware Journal: BMC Nephrol Date: 2013-11-12 Impact factor: 2.388
Authors: Theresa I Shireman; Jonathan D Mahnken; Milind A Phadnis; Edward F Ellerbeck; James B Wetmore Journal: Kidney Blood Press Res Date: 2016-11-21 Impact factor: 2.687
Authors: Ke Wang; Leila R Zelnick; Peter B Imrey; Ian H deBoer; Jonathan Himmelfarb; Michael D Allon; Alfred K Cheung; Laura M Dember; Prabir Roy-Chaudhury; Miguel A Vazquez; John W Kusek; Harold I Feldman; Gerald J Beck; Bryan Kestenbaum Journal: Am J Nephrol Date: 2018-08-02 Impact factor: 3.754